Comment on: A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trials

被引：0
|
作者：
Meyers, Paul A. [1 ,2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pediat, 1275 York Ave, New York, NY 10065 USA
来源：
PEDIATRIC BLOOD & CANCER | 2024年 / 70卷 / 11期
关键词：
D O I：
10.1002/pbc.30617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Initiation of Epoetin-α Therapy at a Starting Dose of 120,000 Units Once Every 3 Weeks in Patients With Cancer Receiving Chemotherapy An Open-Label, Multicenter Study With Randomized and Nonrandomized Treatment Arms
    Glaspy, John A.
    Charu, Veena
    Luo, Donghan
    Moyo, Victor
    Kamin, Marc
    Wilhelm, Francois E.
    CANCER, 2009, 115 (05) : 1121 - 1131
  • [42] All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial
    Huang, Qiu-Sha
    Liu, Yi
    Wang, Jing-Bo
    Peng, Jun
    Hou, Ming
    Liu, Hui
    Feng, Ru
    Wang, Jing-Wen
    Xu, Lan-Ping
    Wang, Yang
    Huang, Xiao-Jun
    Zhang, Xiao-Hui
    LANCET HAEMATOLOGY, 2021, 8 (10): : E688 - E699
  • [43] Both Glimepiride and High-Dose Metformin Are Important for Sustained Glucose Lowering in Japanese Type 2 Diabetes Patients on Glimepiride-Sitagliptin-Metformin Therapy: Subanalysis of a Single-Center, Open-Label, Randomized Study
    Arai, Keiko
    Maeda, Hajime
    Shirabe, Shin-ichiro
    Yamamoto, Ritsuko
    Kumakura, Atsushi
    Yamauchi, Mikio
    Hirao, Tetsuyuki
    Hirao, Setsuko
    Hirao, Koichi
    DIABETES TECHNOLOGY & THERAPEUTICS, 2014, 16 (07) : 442 - 446
  • [44] Evaluation of simplified preanalytical Conditions for the Determination of Methotrexate (MTX) and MTX Metabolites by Liquid Chromatography / Tandem Mass Spectrometry (LC-MS/MS) in Blood Samples from Patients after High-dose MTX Therapy (HD-MTX) and Glucarpidase Treatment
    Knoernschild, F.
    Merz, I
    Jahic, A.
    Kiessling, P.
    Kappert, K.
    Keller, U.
    Schwartz, S.
    Liebig, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 162 - 162
  • [45] Incidence of tuberculosis is low in patients receiving etanercept therapy for the treatment of rheumatoid arthritis: Results from a combined analysis of us and ex-us double-blind trials and their open label extensions
    Wajdula, J.
    MacPeek, D.
    Lin, S.
    Hamza, S.
    Fatenejad, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 195 - 195
  • [46] Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
    Schmitz, Norbert
    Nickelsen, Maike
    Ziepert, Marita
    Haenel, Mathias
    Borchmann, Peter
    Schmidt, Christian
    Viardot, Andreas
    Bentz, Martin
    Peter, Norma
    Ehninger, Gerhard
    Doelken, Gottfried
    Ruebe, Christian
    Truemper, Lorenz
    Rosenwald, Andreas
    Pfreundschuh, Michael
    Loeffler, Markus
    Glass, Bertram
    LANCET ONCOLOGY, 2012, 13 (12): : 1250 - 1259
  • [47] A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX plus /- bevacizumab versus FOLFOX plus /- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer
    Wang, F.
    Xiao, J.
    Zhang, Y.
    Yuan, X.
    He, M.
    Fang, W.
    Zhang, Y.
    Wang, W.
    Hu, X.
    Ma, Z.
    Yao, Y.
    Zhuang, Z.
    Zhou, F.
    Ying, J.
    Yuan, Y.
    Zou, Q.
    Guo, Z.
    Wu, X.
    Jin, Y.
    Mai, Z.
    Guo, Y.
    Xu, R.
    ANNALS OF ONCOLOGY, 2022, 33 : S364 - S364
  • [48] A randomized open-label study of bortezomib, melphalan, and prednisone (VMP) versus daratumumab (DARA) plus VMP in patients with previously untreated multiple myeloma (MM) who are ineligible for high-dose therapy: 54767414MMY3007 (Alcyone).
    Mateos, Mara-Victoria
    Cavo, Michele
    Jakubowiak, Andrzej J.
    Carson, Robin L.
    Qi, Ming
    Bandekar, Rajesh
    Crist, Wendy
    Ahmadi, Tahamtan
    San Miguel, Jesus F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Results of a Phase II Open-Label Trial of Bortezomib in Patients with Multiple Myeloma Who Have Undergone High-Dose Melphalan Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response.
    Rifkin, Robert M.
    Spitzer, Gary
    Greenspan, Andrew
    Schwerkoske, John F.
    Mandanas, Romeo A.
    Stephenson, Joe
    Kannarkat, George T.
    Zhan, Feng
    Asmar, Lina
    Beveridge, Roy
    BLOOD, 2008, 112 (11) : 960 - 960
  • [50] Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial
    Frontzek, Fabian
    Ziepert, Marita
    Nickelsen, Maike
    Altmann, Bettina
    Glass, Bertram
    Haenel, Mathias
    Truemper, Lorenz
    Held, Gerhard
    Bentz, Martin
    Borchmann, Peter
    Dreyling, Martin
    Viardot, Andreas
    Kroschinsky, Frank P.
    Metzner, Bernd
    Staiger, Annette M.
    Horn, Heike
    Ott, German
    Rosenwald, Andreas
    Loeffler, Markus
    Lenz, Georg
    Schmitz, Norbert
    LANCET HAEMATOLOGY, 2021, 8 (04): : E267 - E277
12345